Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invobenitug (Procizumab, PCZ, AK1967) in cardiogenic shock
2024-518450-16-00Phase 2Authorised
- Sponsor
- 4TEEN4 Pharmaceuticals
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2 trial of invobenitug in cardiogenic shock, sponsored by 4TEEN4 Pharmaceuticals. Planned start Jun 2025; status: authorised.
02
Drugs
invobenitug
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2024-518450-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518450-16-00.